Insulet Corp Reports 23.5% Revenue Growth

By Tamara Parker • Wednesday, August 05 10:52 • Permanent Link

Insulet reported second-quarter 2026 revenue of $801.7 million, up 23.5% from a year earlier, with constant-currency growth of 22.7%.

Omnipod revenue totaled $795.9 million, rising 24.6% overall and 23.8% in constant currency. In the U.S., Omnipod revenue increased 20.1% to $544.1 million. International Omnipod revenue climbed 35.5% to $251.8 million, or 32.9% in constant currency.

Drug delivery revenue was $5.8 million.

Operating income came in at $129.7 million, equal to 16.2% of revenue, down 250 basis points from the prior year. Adjusted operating income was $154.5 million, or 19.3% of revenue, up more than 140 basis points.

Net income jumped to $95.0 million, or $1.37 per diluted share, from $22.5 million, or $0.32 per diluted share, a year earlier. Adjusted net income rose 37.4% to $115.0 million, or $1.66 per diluted share, from $83.7 million, or $1.17 per diluted share.

For the third quarter, Insulet guided to total revenue growth of 17.5% to 19.5% in constant currency, with U.S. Omnipod growth of 14% to 16% and international Omnipod growth of 28% to 30%. For the full year, it now expects total revenue growth of 20% to 22%, down from prior guidance of 21% to 23%, while adjusted EPS growth is expected to exceed 30%, up from a prior target of more than 25%.

During the quarter, Insulet launched Omnipod 5 and Omnipod Discover in Spain, bringing Omnipod to 26 countries and Omnipod 5 to 20 countries. It also expanded the Omnipod 5 ecosystem with a next-generation algorithm and added compatibility with Abbott’s FreeStyle Libre 3 Plus. The market has reacted to these announcements by moving the company's shares -17.03% to a price of $138.41. For the full picture, make sure to review INSULET CORP's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.